Skip to content

Study · Not a test of the peptide alone · 2015

4 results

High-resolution mass spectrometry for thymosins detection and characterization.

Cabras T, Iavarone F, Martelli C, Delfino D, Rossetti DV, Inserra I, Manconi B, Desiderio C, Messana I, Hannappel E, Faa G, Castagnola M

Expert opinion on biological therapy22 Jun 2015Cited by 7 (Europe PMC)

PMID26095945 (opens in a new tab)DOI10.1517/14712598.2015.1009887 (opens in a new tab)PepBankPUB-26095945
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueOther

    Several post-translational modifications of thymosin β4 were identified in bodily fluids and in normal and pathological tissues.

    In plain wordsIn lab tests, mass spectrometry found several modified forms of thymosin beta‑4 in body fluids and tissues.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicablePost-translational modifications of thymosin β4
    Study

    n: not reported in source

    bodily fluids and tissues
    Outcome group
    Peptide structure and chemistry · Pharmacology

    Source sentences

    Summary
    In addition to thymosin β4 (Tβ4) and β10 (Tβ10), several post-translational modifications of both these peptides were identified not only in bodily fluids but also in normal and pathological tissues of different origins.
    1 context sentence
    Summary · context
    A top-down proteomic platform based on high-performance liquid chromatography (HPLC) coupled to high-resolution LTQ-Orbitrap mass spectrometry (MS) was applied to the characterization of naturally occurring peptides.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueOther

    Tissue analysis characterized different C-terminal truncated forms of thymosin β4 and other proteolytic fragments.

    In plain wordsIn lab tests, tissue samples held shortened forms of thymosin beta‑4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableC-terminal truncated forms of thymosin β4
    Study

    n: not reported in source

    bodily fluids and tissues
    Outcome group
    Peptide structure and chemistry · Pharmacology

    Source sentences

    Summary
    The analysis of tissue specimens allowed the characterization of different C-terminal truncated forms of Tβ4 and Tβ10 together with other proteolytic fragments.
    1 context sentence
    Summary · context
    A top-down proteomic platform based on high-performance liquid chromatography (HPLC) coupled to high-resolution LTQ-Orbitrap mass spectrometry (MS) was applied to the characterization of naturally occurring peptides.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueOther

    The sulfoxide derivative and the lysine-acetylated derivatives of thymosin β4 were characterized.

    In plain wordsIn lab tests, chemically altered forms of thymosin beta‑4 were identified.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableSulfoxide and acetylated derivatives of thymosin β4
    Study

    n: not reported in source

    bodily fluids and tissues
    Outcome group
    Peptide structure and chemistry · Pharmacology

    Source sentences

    Summary
    The sulfoxide derivative of both Tβ4 and Tβ10 and the acetylated derivatives at lysine residues of Tβ4 were also characterized.
    1 context sentence
    Summary · context
    A top-down proteomic platform based on high-performance liquid chromatography (HPLC) coupled to high-resolution LTQ-Orbitrap mass spectrometry (MS) was applied to the characterization of naturally occurring peptides.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin alpha-1 aloneOther designOther

    A top-down mass spectrometry platform identified proteoforms of thymosin alpha‑1, with other thymosins and proteolytic fragments, in samples of tissues and bodily fluids.

    In plain wordsIn lab tests, mass spectrometry found several forms of natural thymosin alpha‑1 in tissue and fluid samples.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableThymosin alpha 1 proteoforms identified by mass spectrometry
    Study

    n: not reported in source

    Tissues and bodily fluids
    Outcome group
    Analytical methods and detection · Pharmacology

    Source sentences

    Summary
    Different proteoforms of prothymosin α, parathymosin α, thymosin α1 and thymosin α11 together with diverse proteolytic fragments were identified too.
    1 context sentence
    Summary · context
    A top-down proteomic platform based on high-performance liquid chromatography (HPLC) coupled to high-resolution LTQ-Orbitrap mass spectrometry (MS) was applied to the characterization of naturally occurring peptides.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.